Form 8-K - Current report:
SEC Accession No. 0001493152-24-038532
Filing Date
2024-09-27
Accepted
2024-09-27 16:15:19
Documents
13
Period of Report
2024-09-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41021
  Complete submission text file 0001493152-24-038532.txt   217356

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE erna-20240924.xsd EX-101.SCH 3015
3 XBRL LABEL FILE erna-20240924_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE erna-20240924_pre.xml EX-101.PRE 24165
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 241335050
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)